D-19466, A NEW CYCLOBUTANE-PLATINUM COMPLEX WITH ANTITUMOR-ACTIVITY

被引：28

作者：

VOEGELI, R

SCHUMACHER, W

ENGEL, J

RESPONDEK, J

HILGARD, P

机构：

[1] ASTA Pharma AG, Frankfurt, D-6000

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 1990年 / 116卷 / 05期

关键词：

Antitumor activity; D-19466; New drug; Platinum complex; Pre-clinical;

D O I：

10.1007/BF01612990

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

D-19466, a new platinum complex, was characterized. It showed no nephrotoxic side-effects as determined by the measurement of blood urea. It was cytotoxic in vitro for tumor cells in concentrations comparable to or lower than cytotoxic concentrations of cisplatin. It had excellent anticancer activity in vivo against a number of murine experimental tumors, including a cisplatin-resistant P388 line. Clinical evaluation of this compound has therefore been initiated. © 1990 Springer-Verlag.

引用

页码：439 / 442

页数：4

共 7 条

[1] CARBOPLATIN - CURRENT STATUS AND FUTURE-PROSPECTS [J].

CANETTA, R ;

BRAGMAN, K ;

SMALDONE, L ;

ROZENCWEIG, M .

CANCER TREATMENT REVIEWS, 1988, 15 :17-32

[2]

DEVITA VT, 1989, CANCER PRINCIPLES PR, P373

[3] PRIMARY BIOASSAY OF HUMAN MYELOMA STEM-CELLS [J].

HAMBURGER, A ;

SALMON, SE .

JOURNAL OF CLINICAL INVESTIGATION, 1977, 60 (04) :846-854

[4]

ISELT M, 1989, ARZNEIMITTEL-FORSCH, V39-2, P747

[5]

SCHMAHL D, 1956, NATURWISSENSCHAFTEN, V43, P475

[6]

SCHUMACHER W, 1989, 22 HAUPTVERSAMMLUNG, P163

[7] IPROPLATIN AND CARBOPLATIN INDUCED TOXICITIES - OVERVIEW OF PHASE-II CLINICAL-TRIAL CONDUCTED BY THE EORTC EARLY CLINICAL-TRIALS COOPERATIVE GROUP (ECTG) [J].

VANGLABBEKE, M ;

RENARD, J ;

PINEDO, HM ;

CAVALLI, F ;

VERMORKEN, J ;

SESSA, C ;

ABELE, R ;

CLAVEL, M ;

MONFARDINI, S .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (02) :255-262

← 1 →